China may resist US FDA visit to drug facility

China may oppose a visit by the US Food and Drug Administration (FDA) to a facility producing the active ingredients for a drug linked to four deaths and hundreds of allergic reactions, the Wall Street Journal reported. The paper said a deputy director of China’s State Food and Drug Administration said he did not see the need for Americans to come to China. The FDA and Baxter International, which produces the blood thinner heparin, have not released the name of the supplier. The paper named Changzhou SPL Co as one of Baxter’s clients and cited a Changzhou employee as saying the firm was expecting its first visit from the FDA. Changzhou SPL is a joint venture between Wisconin-based Scientific Protein Laboratories and Changzhou Techpool Pharmaceutical Co of China.